Last reviewed · How we verify
AVM0703
At a glance
| Generic name | AVM0703 |
|---|---|
| Also known as | Suprapharmacologic dexamethasone sodium phosphate, Supra-Pharmacologic Dexamethasone Phosphate |
| Sponsor | AVM Biotechnology Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (PHASE1, PHASE2)
- Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (PHASE1)
- Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |